Lupin's Strategic Leap: Expanding Eye Care in Europe Through VISUfarma Acquisition

Lupin Limited has completed its acquisition of VISUfarma B.V., strengthening its specialty care portfolio and presence in Europe. This move significantly expands Lupin's ophthalmology offerings, with over 60 new products. The acquisition supports Lupin's growth in the European market, complementing its existing global operations and expertise.

Lupin Limited, a major player in the global pharmaceutical landscape, has successfully completed its acquisition of VISUfarma B.V., a prominent European specialty pharmaceutical firm focused on ophthalmology. This strategic acquisition is seen as a key milestone in Lupin's ambitious growth strategy, aiming to fortify its presence in the European market.

With the addition of VISUfarma, Lupin has markedly expanded its ophthalmology portfolio, now boasting over 60 branded products that address various eye health issues such as dry eye syndrome, glaucoma, and other complications. The move aligns with the company's vision to meet the escalating demand for cutting-edge eye care solutions.

Lupin CEO Vinita Gupta expressed enthusiasm about this development, highlighting how the acquisition bolsters the company's European commercial infrastructure and accelerates its specialty franchise build-out. VISUfarma CEO Paolo Cioccetti echoed this sentiment, emphasizing the strategic fit and the potential for transformative impact on eye care advancement across Europe.

(With inputs from agencies.)